Zydus Lifesciences’ arm executes asset purchase agreement with BridgeBio

09 Mar 2022 Evaluate

Sentynl Therapeutics, Inc. (Sentynl), a wholly owned subsidiary of Zydus Lifesciences, and BridgeBio Pharma, Inc. (BridgeBio), have executed an asset purchase agreement (the Agreement) for the sale of BridgeBio’s NULIBRY (Fosdenopterin) for injection. NULIBRY is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder.

With the asset purchase of NULIBRY, Zydus Lifesciences aims at bridging unmet healthcare needs of children with rare and orphan paediatric diseases. The company’s wholly owned subsidiary Sentynl is also facilitating early diagnosis and treatment by enhancing awareness, new-born screening, genetic testing and patient support across multiple products and rare diseases including the development of a treatment for Menkes Disease, currently under rolling review by the USFDA, for which it partnered with Cyprium Therapeutics, Inc. (Cyprium).

Zydus Lifesciences is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

1004.00 2.15 (0.21%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.70
Dr. Reddys Lab 1258.55
Cipla 1559.20
Lupin 2198.25
Zydus Lifesciences 1004.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.